Aclaris Therapeutics

ACRS · Nasdaq · United States

Share price · ACRS

$3.50-2.80 (-44.49%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.9M (0.9x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ACRS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 8 Oct 2026+11.5%
  2. 7 Oct 2026-8.1%
  3. 6 Oct 2026-13.3%
  4. 1 Oct 2026-16.2%
  5. 9 Sep 2026-8.3%
  6. 18 Aug 2026+6.5%

    Nothing announced by ACRS that day or the session before.

  7. 3 Aug 2026+6.3%
  8. 2 Jun 2026+6.7%
  9. 20 Jan 2026+69.1%
  10. 8 Dec 2025+12.3%

Share of unusual movement by asset

For each asset, the share of ACRS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Modzatinib
events and moves
7shown from 8 days
ATI-052
events and moves
5shown from 8 days
Bosakitug
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—2%
Other company news (earnings, financing, releases naming no asset)—28%
Sessions with no dated event—70%

Assets

(4 total)
4Total Assets
0Approved
0Phase 3 / Filed
4Phase 1–2 / Early
1Diseases
Showing 4 of 4 assets
Target & Modality
Phase 2
TSLPMonoclonal antibody
Atopic Dermatitis
LepzacitinibNo recent activity
Phase 2
JAK1/JAK3Small molecule
Atopic Dermatitis
Phase 2
ITK and JAK3Small molecule
Atopic Dermatitis
Preclinical / Unstaged
IL-4Rα and TSLPMultispecific antibody
Atopic Dermatitis

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
March 2029 (1)
ModzatinibPhase 2Lichen Planus
Est. primary completion 2029-03 · NCT07935590 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

16 November 2026Topline resultBosakitugPhase 2 ADMIRATION trial of bosakitug misses primary endpoint
27 October 2026Topline resultATI-052Phase 1b POC primary analysis in atopic dermatitis
29 July 2025Topline resultATI-2138Open-label Phase 2a of ATI-2138 in atopic dermatitis: topline results
Aclaris Therapeutics · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$1.5M$16M$20M+ $94M short-term inv.$19M-$24M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$1.6M$18M$19M+ $72M short-term inv.$22M-$20M operating cash flowreport ↗
2026-Q1$2.0M$16M$191M$20Mreport ↗
2025-Q3$3.3M$13M$25M+ $71M short-term inv.$15M-$11M operating cash flowreport ↗
2025-Q2$1.8M$11M$25M+ $74M short-term inv.$15M-$10.0M operating cash flowreport ↗
2025-Q1$1.5M$12M$30M+ $75M short-term inv.$15M-$13M operating cash flowreport ↗
2024-Q3$4.3M$6.0M$48M+ $80M short-term inv.$7.6M$22M operating cash flowreport ↗
2024-Q2$2.8M$8.8M$23M+ $88M short-term inv.$11M-$12M operating cash flowreport ↗
2024-Q1$2.4M$9.8M$36M+ $92M short-term inv.$17M-$21M operating cash flowreport ↗
2023-Q3$9.3M$24M$39M+ $64M short-term inv.$29M-$25M operating cash flowreport ↗
2023-Q2$1.9M$25M$31M+ $89M short-term inv.$30M-$21M operating cash flowreport ↗
2023-Q1$2.5M$23M$45M+ $126M short-term inv.$28M-$26M operating cash flowreport ↗
2022-Q3$19M$24M$62M+ $186M short-term inv.$20M-$7.8M operating cash flowreport ↗
2022-Q2$1.5M$19M$68M+ $180M short-term inv.$21M-$20M operating cash flowreport ↗
2022-Q1$1.4M$14M$36M+ $143M short-term inv.$19M-$21M operating cash flowreport ↗
2021-Q3$1.7M$14M$54M+ $144M short-term inv.$21M-$11M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$7.8M$53M$20M+ $71M short-term inv.$16M-$47M operating cash flowreport ↗

Aclaris reported full-year 2025 revenue of $7.83M, down 58.2% YoY, and R&D spend of $52.65M, up 56.7% YoY. Cash and equivalents were $19.96M, while cash, cash equivalents and marketable securities totaled $151.4M. The full-year net loss was $64.92M, with basic and diluted net loss per share of $0.53.

Management said existing cash, cash equivalents and marketable securities are expected to fund operations into the second half of 2028, excluding potential business development, financing, or planned Phase 2b trial costs. Clinical updates included positive interim Phase 1a SAD/MAD results for ATI-052, with complete top-line results expected in the second quarter of 2026 and Phase 1b proof-of-concept trials in atopic dermatitis and asthma underway; a Phase 2b program is planned for the second half of 2026. The company also expects top-line results from the bosakitug Phase 2 trial in atopic dermatitis in the second half of 2026, plans to file an IND for ATI-9494 in the second half of 2026, and reported that ATI-2138 demonstrated 93% mean hair regrowth in a murine alopecia model.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$19M$34M$25M+ $89M short-term inv.$33M-$20M operating cash flowreport ↗
2023-FY$31M$98M$40M+ $79M short-term inv.$22M-$78M operating cash flowreport ↗
2022-FY$30M$78M$45M+ $172M short-term inv.$22M-$68M operating cash flowreport ↗
2021-FY$6.8M$44M$27M+ $164M short-term inv.$23M-$52M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 1 sale ($1.4M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-08-01Kolbeck Roland Wilhelm · Chief Scientific OfficerOption exercise36,375——Form 4
2026-08-01Kolbeck Roland Wilhelm · Chief Scientific OfficerTax withholding12,385$5.20$64KForm 4
2026-08-01Kolbeck Roland Wilhelm · Chief Scientific OfficerOption exercise (derivative)36,375——Form 4
2026-06-05GOWEN MAXINE · directorOption exercise11,580——Form 4
2026-06-05MILANO VINCENT · directorOption exercise11,580——Form 4
2026-06-05Molineaux Christopher P. · directorOption exercise11,580——Form 4
2026-06-05Humphries William D. · directorOption exercise11,580——Form 4
2026-06-05SCHIFF ANDREW N · directorOption exercise11,580——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 136 reporting institutions held 110.5M shares ($406.2M, 69.7% of shares outstanding).

#InstitutionSharesValue
1BML Capital Management, LLC14,250,000$53.4M
2Deep Track Capital, LP9,345,000$35.0M
3BlackRock, Inc.7,407,065$27.8M
4RA CAPITAL MANAGEMENT, L.P.6,804,072$25.5M
5Vivo Capital, LLC6,666,666$25.0M
6VANGUARD CAPITAL MANAGEMENT LLC5,167,469$19.4M
7Frazier Life Sciences Management, L.P.4,925,374$18.5M
8Rock Springs Capital Management LP4,472,650$16.8M
9Decheng Capital LLC4,041,736$15.2M
10ADAGE CAPITAL PARTNERS GP, L.L.C.3,871,000$14.5M
11Balyasny Asset Management L.P.3,361,328$12.6M
12Kalehua Capital Management LLC3,169,921$11.9M
13MORGAN STANLEY2,746,302$10.3M
14GEODE CAPITAL MANAGEMENT, LLC2,423,691$9.1M
15CITADEL ADVISORS LLC2,249,319$8.4M